Theriva Biologics announced the appointment of Dr. Ramon Alemany as Senior Vice President of Discovery, effective immediately. Dr. Alemany will oversee Theriva's discovery and development pipeline and will continue to serve as Chair of the Scientific Advisory Board. Dr. Alemany is Head of the Immunotherapy and Virotherapy Group at the ProCURE Program of the Catalan Institute of Oncology (ICO) and the Oncobell Program of the Biomedical Research Institute of Bellvitge (IDIBELL).

Dr. Alemany's laboratory has developed unique oncolytic adenoviruses that are highly selective for replication in tumor cells, with modifications for tumor-targeting, tumor stroma degradation, evasion of neutralizing antibodies, and promotion of tumor immunogenicity. Ramon Alemany, Ph.D., is an OV pioneer and an expert in oncolytic adenoviruses. He is Head of the Immunotherapy and Virotherapy Group at the Translational Research Laboratory of the ICO /IDIBELL, is co-founder of VCN Biosciences, a consultant for several virotherapy companies and a former President of the Spanish Society of Gene and Cell Therapy.

Following Dr. Alemany's Ph.D., at the University of Barcelona, he focused on the development of adenovirus vectors expressing anti-K-Ras and p53 at the MD Anderson Cancer Center (Houston, TX). Dr. Alemany has held leading research positions at the Gene Therapy Unit at Baxter Healthcare (Round Lake, IL) and at the University of Alabama (Birmingham, AL), where he collaborated with a team of top-level virologists. Dr. Alemany is the inventor on 15 oncolytic adenoviruses patents to date and has an outstanding publication record, with more than 160 papers.

He also serves as editor in several gene therapy journals.